Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen

Clinical and Experimental Metastasis

Volumn 18, Issue 1, 2000, Pages 15-20

  Gasparini, Giampietro ^a   Fanelli, Massimo ^a   Boracchi, Patrizia ^b   Morabito, Alessandro ^a   Locopo, Nathalia ^a   Biganzoli, Elia ^c  

^a Division of Medical Oncology   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant therapy; Angiogenesis; Metastasis; Tamoxifen

Indexed keywords

CD31 ANTIGEN; ESTROGEN RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; DRUG MECHANISM; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; TAMOXIFEN;

EID: 0035133076     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026574818241     Document Type: Article

References (31)

1. Angiogenesis in breast cancer: Role in biology, tumor progression, and prognosis
2. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer
3. Time distribution of the reccurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy
4. Annual hazard rates of recurrence for breast cancer after primary therapy
5. Dormancy of mammary carcinoma after mastectomy
6. Cancer dormancy: Opportunities for new therapeutic approaches
7. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
8. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
9. Angiostatin induces and sustains dormancy of human primary tumors in mice
10. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
11. The tumor dormant state
12. Tumor dormancy and cell signaling-III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells
13. Role of integrins and other cell adhesion molecules in tumor progression and metastasis
14. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction
15. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
16. Inhibition of angiogenesis by antiestrogens
17. Down-regulation of transforming growth factor-α by tamoxifen in human breast cancer
18. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients
19. Immunohistochemical demonstration of estrogen receptors (ER) in formalin - Fixed paraffin-embedded human breast cancer tissue by use of a monoclonal anti-body to ER
20. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
21. Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
22. Logistic regression, survival analysis, and the Kaplan-Meier curve
23. Information theory and an extension of the maximum likelihood principle
24. Time-dependence of hazard ratios for prognostic factors in primary breast cancer
25. Transforming growth factor alpha: A more potent angiogenic mediator than epidermal growth factor
26. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
27. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth
28. 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site
29. The rationale and future potential of angiogenesis inhibitors in neoplasia
30. Clinical relevance of vascular endothelial growth factor (VEGF) and thymidinc phosphorylase (TP) in patients with node-positive breast cancer treated either with adjuvant chemotherapy or hormonetherapy
31. Molecular-targeted anticancer therapy: Challanges related to study-design and choice of proper endpoints